Get the Stockscreener App
1.66
1.19%
-0.02
After Hours:
1.65
-0.01
-0.60%
Enveric Biosciences Inc stock is traded at $1.66, with a volume of 239.42K.
It is down -1.19% in the last 24 hours and down -78.08% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.
See More
Previous Close:
$1.68
Open:
$1.69
24h Volume:
239.42K
Relative Volume:
1.79
Market Cap:
$3.19M
Revenue:
-
Net Income/Loss:
$-15.08M
P/E Ratio:
-0.2586
EPS:
-6.42
Net Cash Flow:
$-11.56M
1W Performance:
-20.57%
1M Performance:
-78.08%
6M Performance:
-80.57%
1Y Performance:
-86.46%
1-Day Range:
$1.57
$1.72
1-Week Range:
$1.57
$2.08
52-Week Range:
$1.57
$43.80
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
239-302-1707
Address
4851 TAMIAMI TRAIL N, SUITE 200, NAPLES
Compare ENVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.66 | 3.19M | 0 | -15.08M | -11.56M | -6.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences unit in licensing pacts with Restoration Biologics - TipRanks
Looking For A Good Stock? Let This Enveric Biosciences Inc (NASDAQ: ENVB) Analysis Help. - Stocks Register
Is Enveric Biosciences Inc (ENVB) worth investing in despite its undervalued state? - US Post News
A New Horizon in Joint Disease Treatment: Enveric Biosciences and Restoration Biologics Forge Licensing Agreements - Microdose Psychedelic Insights
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease - Marketscreener.com
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease - Benzinga
Major Biotech Licensing Deal: Enveric's $82M Agreement Targets Revolutionary Arthritis Therapy - StockTitan
Enveric Biosciences Announces Closing Of $5 Million Public Offering -February 03, 2025 at 05:37 pm EST - Marketscreener.com
Biotech Capital Raise: Enveric Secures Fresh $5M Funding Through Strategic Share Offering - StockTitan
Market Movers: Reborn Coffee, Nxu, and Perfect Moment Surge While Enveric Biosciences Plunges - HPBL
Stock summary: Enveric Biosciences declined by 55.78% over the past five days amid $5 million public offerings made by the company - Business Upturn
Enveric Biosciences stock plummets after pricing $5M capital raise - MSN
Enveric Biosciences Prices of $5 Million Public Offering - citybiz
Enveric Biosciences Down Sharply After Public Offering - MarketWatch
Stock market news: Enveric Biosciences -44.59%, Benson Hill -40.15% among biggest losers during mid day trading - Business Upturn
Dow Edges Lower; Exxon Mobil Earnings Top Views - Benzinga
Stock market today: Enveric Biosciences -47.18%, Benson Hill -42.53% among biggest losers in early trading - Business Upturn
Stock market today: Perfect Moment posted rise of 89.86% whereas Enveric Biosciences saw fall of 45.64% in early trading - Business Upturn
Nasdaq Jumps Over 150 Points; Apple Posts Upbeat Earnings - Benzinga
Enveric Biosciences Prices $5 Million Public Offering; Shares Drop 40% in Premarket Trading - Yahoo Finance
Enveric’s stock split leads to quick $5M raise but shares slide - Green Market Report
Biotech Funding Alert: Enveric Secures $5M to Advance Neural Therapeutics Pipeline - StockTitan
Enveric Biosciences Announces Pricing of $5 Million Public Offering - Business Wire
Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office - BioSpace
Enveric Passes Key Milestone on Patent Path for Mental-Health Treatment - MarketWatch
Enveric Biosciences stock hits 52-week low at $0.29 By Investing.com - Investing.com Australia
Enveric Biosciences stock hits 52-week low at $0.29 - MSN
Jay Pharma Inc. Announces Appointment of Sara Dakar as Vice President, Product Development - Marketscreener.com
AMERI Holdings, Inc. and Jay Pharma Inc. Announce Dave Johnson to Assume the Chairman & CEO Role Upon the Closing of Amalgamation Agreement - Marketscreener.com
AMERI Holdings, Inc. Announces Executive Changes -April 08, 2019 at 08:00 am EDT - Marketscreener.com
AMERI Holdings, Inc. Announces Board Changes -December 12, 2018 at 06:59 am EST - Marketscreener.com
R. James Woolsey Joins AMERI Holdings as Strategy Consultant -January 27, 2020 at 08:00 am EST - Marketscreener.com
Ameri Holdings, Inc. Approves Director Changes -August 17, 2018 at 08:00 am EDT - Marketscreener.com
Ameri Holdings, Inc. Announces Board Changes -April 02, 2019 at 04:01 pm EDT - Marketscreener.com
Robert Wilkins Joins Jay Pharma as Chief Medical Officer -July 29, 2020 at 09:00 am EDT - Marketscreener.com
Ameri Holdings, Inc. Appoints David Luci as a Director of the Company, Effective Immediately - Marketscreener.com
Enveric Biosciences Appoints Arash Asher to Scientific Advisory Board -May 12, 2021 at 07:30 am EDT - Marketscreener.com
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders - Marketscreener.com
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally - Marketscreener.com
Enveric Biosciences Announces 1-for-15 Reverse Stock Split - MSN
Enveric Biosciences Announces 1-for-15 Reverse Stock Split By Investing.com - Investing.com Australia
Analyzing Enveric Biosciences (NASDAQ:ENVB) and TuHURA Biosciences (NASDAQ:HURA) - Defense World
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025” - BioSpace
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8 - Business Wire
Enveric Biosciences CEO to Present Future of Psychedelics Vision at Major JP Morgan Week Events - StockTitan
Enveric Biosciences to Release Investor Presentation - TipRanks
ENVB Stock Touches 52-Week Low at $0.3 Amid Market Challenges - Investing.com Nigeria
Enveric Biosciences (NASDAQ:ENVB) Shares Down 4.6% – Here’s Why - Defense World
Why Viking Therapeutics Tumbled by More Than 10% This Week - AOL
Enveric Biosciences Receives Two US Patents for Psilocybin Derivatives - Microdose Psychedelic Insights
Enveric Biosciences secures patents for neuroplasticity drugs By Investing.com - Investing.com Canada
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):